Back to Top Skip to main content Skip to sub-navigation

DOD participates in new COVID-19 antibody combination prevention trial

Woman gets blood drawn Miranda Heilweil gets her blood drawn at Madigan Army Medical Center, Washington, one of five DOD sites where the STORM CHASER trial is studying the efficacy of an antibody product that could prevent COVID-19 in people who have been exposed to the virus within eight days. (U.S. Army photo by Janell Cain)

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | MHS Toolkits and Branding Guidance

While the Military Health System continues to support the development and distribution of COVID-19 vaccines to counter the ongoing public health threat of the disease, it’s investing in other efforts to counter the SARS-CoV-2 virus.

One of those includes evolving therapeutics as part of the U.S. government’s COVID-19 response through clinical trials of a long-acting antibody combination medicine to prevent COVID-19 among people who have been exposed to the disease.

The intramuscular long-acting antibody product, called AZD7442 and developed by AstraZeneca, is undergoing a phase III clinical trial at five Department of Defense sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.

“This study will run for one year, although interim and primary analyses will likely occur much earlier in 2021,” said Dr. Simon Pollett, associate scientific director and COVID-19 research area director at the Uniformed Services University of the Health Science’s (USU) Infectious Diseases Clinical Research Program (IDCRP).

Under the name STORM CHASER, Pollett’s program is coordinating teams of physicians, nurses, pharmacists, and clinical research staff at Tripler Army Medical Center in Hawaii, Madigan Army Medical Center in Washington, William Beaumont Army Medical Center in Texas, Naval Medical Center Portsmouth in Virginia, and USU in Maryland. The lead investigators at these sites are Army Col. Viseth Ngauy, Army Col. Anjali Kunz, Dr. Gina Kubicz, Navy Lt. Cmdr. Tida Lee, and Army Lt. Col. Jeffrey Livezey, respectively.

This study is designed to prevent the development of illness in people who have been exposed to COVID-19 in care homes and sites with enhanced risk of disease transmission, under the sponsorship of AstraZeneca with support from the U.S. health information technology and clinical research firm IQVIA. IDCRP is supported through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Primarily, STORM CHASER seeks to determine if the antibody injection can prevent COVID-19 in people who were exposed to the SARS-CoV-2 virus – which causes the disease – within the last eight days, but have not yet developed symptoms, explained Pollett. “This may include those exposed by household contacts, in crowded working conditions, in health care settings, and other scenarios,” he added.

A secondary objective of the study is examining whether the antibody injection can reduce viral shedding in those who may develop the disease after receiving the injection, said Pollett. Viral shedding occurs when the virus replicates inside the body and is released to the environment, making the host person contagious to others.

“Reduced viral shedding may perhaps correlate with reduced transmissibility, but this requires further study,” said Pollett.

STORM CHASER also aims to see if individuals who receive the AZD7442 injection after SARS-CoV-2 exposure experience less severe symptoms of COVID-19. Likewise, the clinical trial seeks to explore “sequencing of breakthrough virus to look at antibody escape mutations,” said Navy Capt. Timothy Burgess, IDRCP director. This will help determine whether AZD7442 protects across a range of SARS-CoV-2 strains, including newly emerged variants.

AZD7442 contains infection-fighting proteins called monoclonal antibodies that work to neutralize the virus, thus preventing COVID-19. Each dose is given once as two intramuscular shots in each gluteal region, within eight days of exposure.

If clinical trials are successful and the product receives emergency use authorization from the Food and Drug Administration, this investigational product would become another tool to defeat the COVID-19 pandemic. Two vaccines, by Pfizer-BioNTech and Moderna, are available to the U.S. population older than 16 and 18 years of age, respectively, under FDA’s EUA, with three more vaccines, including AstraZeneca’s, currently in clinical trials.

The vaccines work inside the body by triggering the immune system to make antibodies that will block or kill the SARS-CoV-2 spike protein if it enters the body, which results in immunity to coronavirus. They are given to healthy individuals who have not been exposed to the virus to protect them against getting seriously ill from the disease if they become infected or exposed, and studies are still being conducted to gauge their ability to keep people from spreading the virus.

AZD7442 may provide very rapid protection against COVID-19 in individuals who have been exposed because it is given while the virus is incubating, said Burgess. But those who have already received the COVID-19 vaccine are not eligible to participate in the study.

“The investigational product is intended to provide rapid immunity after exposure, with up to six months of protection thereafter,” said Burgess. “STORM CHASER is examining the efficacy of this.”

If the study is successful in achieving its objective of preventing COVID-19 after exposure, the hope, according to Pollett, is that transmission chains will also be stopped by preventing such COVID-19 cases, but further study is required.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.

If interested in participating in the STORM CHASER trial - please contact Julia Rozman at: julia.rozman.ctr@usuhs.edu.

You also may be interested in...

Get to Know the COVID-19 Vaccines

Infographic
6/9/2021
Assures beneficiaries that the COVID-19 vaccines will not give you the virus, does not affect our DNA, and is safe.

This graphic that assures beneficiaries that the vaccines will not give you the virus, does not affect our DNA, and is safe. Graphics include a person receiving the vaccine and a comparison graphic of COVID-19 trials versus other trials.

Recommended Content:

Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

Get to Know the COVID-19 Vaccines (Combined)

Publication
6/9/2021

The Pfizer-BioNTech, Moderna, and Janssen (Johnson & Johnson) COVID-19 vaccines were developed to prevent infection from the virus that causes COVID-19. Learn about the vaccines, how they work and safety precautions.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | Getting the COVID-19 Vaccine | COVID-19 Vaccine Efforts

Get to Know the COVID-19 Vaccines

Publication
6/9/2021

The Pfizer-BioNTech, Moderna, and Janssen (Johnson & Johnson) COVID-19 vaccines were developed to prevent infection from the virus that causes COVID-19.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

COVID-19 Vaccine Safety Monitoring

Publication
6/9/2021

The FDA and CDC continue to monitor the safety of COVID-19 vaccines. CDC has an independent group of experts that reviews all the safety data as it comes in and provides regular safety updates.

Recommended Content:

Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

How COVID-19 Vaccines Work

Publication
6/9/2021

Learn how the different COVID-19 vaccines work.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

Got Your 6 - June 6, 2021

Video
6/7/2021
Video screen image for the June 6, 2021 Got Your Six video

"Got Your 6" is TRICARE's COVID-19 vaccine video series that delivers important information and updates, three times a month. It includes the latest information about DoD vaccine distribution, the TRICARE health benefit, and vaccine availability for a DoD-affiliated, and TRICARE beneficiary audience.

Recommended Content:

MHS Toolkits and Branding Guidance | MHS Toolkits and Branding Guidance | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

Army’s 773rd administers mobile COVID-19 testing during DEF21

Article
6/4/2021
Three military personnel, wearing masks and lab coats, pose for a picture in an Albanian lab.

Approximately 800 Army Reserve soldiers from the U.S. and Europe participated in DEFENDER-Europe 21.

Recommended Content:

Health Readiness | Coronavirus | COVID-19 Vaccine Toolkit | Readiness Capabilities

Mental Health Panel Discusses Impact of COVID-19

Article
6/3/2021
Military personnel wearing face mask speaking on a panel

Walter Reed Bethesda hosts mental health panel to discuss the impacts of COVID-19.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | Psychological Fitness

Based on data, MHS experts encourage vaccines for adolescents

Article
6/1/2021
Sister and brother smiling at each other

With the Pfizer vaccine approved for youth ages 12 to 15, MHS adolescents are lining up to get the COVID-19 vaccine.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts | Children's Health | Vaccine Eligibility

“Shots in arms” – OPT planned & coordinated to meet COVID-19 mission

Article
5/28/2021
Military personnel sitting around a table talking

The Department of Defense’s COVID-19 Operational Planning Team has been the quiet force behind the DOD’s vaccination effort since November.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

VAX Facts: Which Vaccine is Right for Me?

Video
5/28/2021
DHA Seal

Dr. LC Collins talks about the importance of getting the first vaccine available to you. Don't hold out for a certain brand; they're all safe and effective.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vax Facts | Coronavirus | COVID-19 Vaccine Efforts

VAX Facts: Breastfeeding after the COVID-19 Vaccine

Video
5/28/2021
DHA Seal

Dr. LC Collins encourages people who are breastfeeding to get the vaccine. Since the vaccine doesn't contain live virus, you can't pass COVID to your baby.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vax Facts | Coronavirus | COVID-19 Vaccine Efforts

What is an mRNA vaccine?

Video
5/28/2021
DHA Seal

Dr. LC Collins explains how mRNA vaccines work to protect you from COVID-19.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vax Facts | Coronavirus | COVID-19 Vaccine Efforts

Are mRNA vaccines safe?

Video
5/28/2021
DHA Seal

Dr. LC Collins explains the years of research and ongoing monitoring to show how mRNA vaccines are safe and effective.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vax Facts | Coronavirus | COVID-19 Vaccine Efforts

VAX Facts: Do I Need the Vaccine if I Had COVID?

Video
5/28/2021
DHA Seal

Dr. LC Collins talks about the importance of getting vaccinated even if you already had COVID. We're not sure how long natural immunity lasts, so getting vaccinated is the best way to protect yourself.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vax Facts | Coronavirus | COVID-19 Vaccine Efforts
<< < 1 2 3 4 5  ... > >> 
Showing results 46 - 60 Page 4 of 40

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.